BACKGROUND: Reduced microbial diversity has been associated with inflammatory bowel disease (IBD) and probiotic bacteria have been proposed for its prevention and/or treatment. Nevertheless, comparative studies of strains of the same subspecies for specific health benefits are scarce. Here we compared two Bifidobacterium longum ssp. longum strains for their capacity to prevent experimental colitis. METHODS: Immunomodulatory properties of nine probiotic bifidobacteria were assessed by stimulation of murine splenocytes. The immune responses to B. longum ssp. longum CCM 7952 (Bl 7952) and CCDM 372 (Bl 372) were further characterized by stimulation of bone marrow-derived dendritic cell, HEK293/TLR2 or HEK293/NOD2 cells. A mouse model of dextran sulphate sodium (DSS)-induced colitis was used to compare their beneficial effects in vivo. RESULTS: The nine bifidobacteria exhibited strain-specific abilities to induce cytokine production. Bl 372 induced higher levels of both pro- and anti-inflammatory cytokines in spleen and dendritic cell cultures compared to Bl 7952. Both strains engaged TLR2 and contain ligands for NOD2. In a mouse model of DSS-induced colitis, Bl 7952, but not Bl 372, reduced clinical symptoms and preserved expression of tight junction proteins. Importantly, Bl 7952 improved intestinal barrier function as demonstrated by reduced FITC-dextran levels in serum. CONCLUSIONS: We have shown that Bl 7952, but not Bl 372, protected mice from the development of experimental colitis. Our data suggest that although some immunomodulatory properties might be widespread among the genus Bifidobacterium, others may be rare and characteristic only for a specific strain. Therefore, careful selection might be crucial in providing beneficial outcome in clinical trials with probiotics in IBD.

Brno University of Technology Faculty of Chemistry Brno Czech Republic

Dairy Research Institute Ltd Prague Czech Republic

Institute of Specific Prophylaxis and Tropical Medicine Center for Pathophysiology Infectiology and Immunology Medical University of Vienna Vienna Austria

Laboratory of Cellular and Molecular Immunology Institute of Microbiology of the Czech Academy of Sciences v v i Prague Czech Republic

Laboratory of Gnotobiology Institute of Microbiology of the Czech Academy of Sciences v v i Novy Hradek Czech Republic

Zobrazit více v PubMed

Baumgart DC, Sandborn WJ. Crohn's disease. The Lancet. 2012;380(9853):1590–605. 10.1016/s0140-6736(12)60026-9 PubMed DOI

Boirivant M, Cossu A. Inflammatory bowel disease. Oral Dis. 2012;18(1):1–15. Epub 2011/05/14. 10.1111/j.1601-0825.2011.01811.x . PubMed DOI

Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54 e42; quiz e30. Epub 2011/10/18. 10.1053/j.gastro.2011.10.001 . PubMed DOI

Weinstock JV, Elliott DE. Translatability of helminth therapy in inflammatory bowel diseases. Int J Parasitol. 2013;43(3–4):245–51. Epub 2012/11/28. 10.1016/j.ijpara.2012.10.016 PubMed DOI PMC

Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9(10):599–608. Epub 2012/08/22. 10.1038/nrgastro.2012.152 . PubMed DOI

Favier C, Neut C, Mizon C, Cortot A, Colombel JF, Mizon J. Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig Dis Sci. 1997;42(4):817–22. . PubMed

Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134(2):577–94. Epub 2008/02/05. 10.1053/j.gastro.2007.11.059 . PubMed DOI

Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003;361(9356):512–9. 10.1016/S0140-6736(03)12489-0 . PubMed DOI

Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185–210. Epub 2011/05/10. 10.2147/DDDT.S11290 PubMed DOI PMC

Zenlea T, Peppercorn MA. Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol. 2014;20(12):3146–52. Epub 2014/04/04. 10.3748/wjg.v20.i12.3146 PubMed DOI PMC

Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100(7):1539–46. Epub 2005/06/30. 10.1111/j.1572-0241.2005.41794.x . PubMed DOI

Verbeke KA, Boesmans L, Boets E. Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation? Proc Nutr Soc. 2014;73(4):490–7. Epub 2014/06/28. 10.1017/S0029665114000639 . PubMed DOI

Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13(8):1103–8. . PubMed

Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104(2):437–43. Epub 2009/01/29. 10.1038/ajg.2008.118 . PubMed DOI

Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51(3):405–9. PubMed PMC

Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci. 2008;53(9):2524–31. 10.1007/s10620-007-0171-0 . PubMed DOI

Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2006;(4):CD004826 10.1002/14651858.CD004826.pub2 . PubMed DOI

Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis. 2011;5(2):115–21. Epub 2011/04/02. 10.1016/j.crohns.2010.11.004 . PubMed DOI

Perse M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol. 2012;2012:718617 Epub 2012/06/06. 10.1155/2012/718617 PubMed DOI PMC

Neurath MF. Animal models of inflammatory bowel diseases: illuminating the pathogenesis of colitis, ileitis and cancer. Dig Dis. 2012;30 Suppl 1:91–4. Epub 2012/10/25. 10.1159/000341131 . PubMed DOI

Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis. 2009;15(3):341–52. Epub 2008/10/24. 10.1002/ibd.20753 PubMed DOI PMC

Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98(3):694–702. . PubMed

Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annual review of immunology. 2002;20:495–549. 10.1146/annurev.immunol.20.100301.064816 . PubMed DOI

Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2(3):541–6. 10.1038/nprot.2007.41 . PubMed DOI

Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. The Journal of surgical research. 2007;140(1):12–9. Epub 2007/04/10. 10.1016/j.jss.2006.07.050 . PubMed DOI

Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet. 1993;341(8858):1437–9. . PubMed

Turroni F, Foroni E, Pizzetti P, Giubellini V, Ribbera A, Merusi P, et al. Exploring the diversity of the bifidobacterial population in the human intestinal tract. Appl Environ Microbiol. 2009;75(6):1534–45. 10.1128/AEM.02216-08 PubMed DOI PMC

Turroni F, Marchesi JR, Foroni E, Gueimonde M, Shanahan F, Margolles A, et al. Microbiomic analysis of the bifidobacterial population in the human distal gut. ISME J. 2009;3(6):745–51. 10.1038/ismej.2009.19 . PubMed DOI

Ventura M, Turroni F, Lugli GA, van Sinderen D. Bifidobacteria and humans: our special friends, from ecological to genomics perspectives. J Sci Food Agric. 2014;94(2):163–8. 10.1002/jsfa.6356 . PubMed DOI

Matsuki T, Watanabe K, Tanaka R, Fukuda M, Oyaizu H. Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA-gene-targeted species-specific primers. Appl Environ Microbiol. 1999;65(10):4506–12. PubMed PMC

Makino H, Kushiro A, Ishikawa E, Muylaert D, Kubota H, Sakai T, et al. Transmission of intestinal Bifidobacterium longum subsp. longum strains from mother to infant, determined by multilocus sequencing typing and amplified fragment length polymorphism. Applied and environmental microbiology. 2011;77(19):6788–93. 10.1128/AEM.05346-11 PubMed DOI PMC

Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil D A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54(2):242–9. 10.1136/gut.2004.044834 PubMed DOI PMC

Fujiwara M, Kaneko T, Iwana H, Taketomo N, Tsunoo H, Kanno J, et al. Inhibitory effects of Bifidobacterium longum on experimental ulcerative colitis induced in mice by synthetic dextran sulfate sodium. Digestion. 2003;67(1–2):90–5. 69704. . PubMed

Schwarzer M, Srutkova D, Schabussova I, Hudcovic T, Akgun J, Wiedermann U, et al. Neonatal colonization of germ-free mice with Bifidobacterium longum prevents allergic sensitization to major birch pollen allergen Bet v 1. Vaccine. 2013;31(46):5405–12. 10.1016/j.vaccine.2013.09.014 . PubMed DOI

Schabussova I, Hufnagl K, Wild C, Nutten S, Zuercher AW, Mercenier A, et al. Distinctive anti-allergy properties of two probiotic bacterial strains in a mouse model of allergic poly-sensitization. Vaccine. 2011;29(10):1981–90. 10.1016/j.vaccine.2010.12.101 . PubMed DOI

Srutkova D, Spanova A, Spano M, Drab V, Schwarzer M, Kozakova H, et al. Efficiency of PCR-based methods in discriminating Bifidobacterium longum ssp. longum and Bifidobacterium longum ssp. infantis strains of human origin. J Microbiol Methods. 2011;87(1):10–6. 10.1016/j.mimet.2011.06.014 . PubMed DOI

Krizova J, Spanova A, Rittich B. Evaluation of amplified ribosomal DNA restriction analysis (ARDRA) and species-specific PCR for identification of Bifidobacterium species. Syst Appl Microbiol. 2006;29(1):36–44. 10.1016/j.syapm.2005.07.003 . PubMed DOI

Repa A, Grangette C, Daniel C, Hochreiter R, Hoffmann-Sommergruber K, Thalhamer J, et al. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine. 2003;22(1):87–95. . PubMed

Schabussova I, Hufnagl K, Tang ML, Hoflehner E, Wagner A, Loupal G, et al. Perinatal maternal administration of Lactobacillus paracasei NCC 2461 prevents allergic inflammation in a mouse model of birch pollen allergy. PloS one. 2012;7(7):e40271 10.1371/journal.pone.0040271 PubMed DOI PMC

Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993;69(2):238–49. . PubMed

Hudcovic T, Stepankova R, Cebra J, Tlaskalova-Hogenova H. The role of microflora in the development of intestinal inflammation: acute and chronic colitis induced by dextran sulfate in germ-free and conventionally reared immunocompetent and immunodeficient mice. Folia microbiologica. 2001;46(6):565–72. . PubMed

Cinova J, De Palma G, Stepankova R, Kofronova O, Kverka M, Sanz Y, et al. Role of intestinal bacteria in gliadin-induced changes in intestinal mucosa: study in germ-free rats. PloS one. 2011;6(1):e16169 10.1371/journal.pone.0016169 PubMed DOI PMC

Zakostelska Z, Kverka M, Klimesova K, Rossmann P, Mrazek J, Kopecny J, et al. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PloS one. 2011;6(11):e27961 10.1371/journal.pone.0027961 PubMed DOI PMC

Kole A, Maloy KJ. Control of intestinal inflammation by interleukin-10. Current topics in microbiology and immunology. 2014;380:19–38. Epub 2014/07/10. 10.1007/978-3-662-43492-5_2 . PubMed DOI

Persson EK, Scott CL, Mowat AM, Agace WW. Dendritic cell subsets in the intestinal lamina propria: ontogeny and function. Eur J Immunol. 2013;43(12):3098–107. 10.1002/eji.201343740 PubMed DOI PMC

Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124(1):3–20; quiz 1–2. 10.1016/j.jaci.2009.05.038 PubMed DOI PMC

Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146(6):1489–99. 10.1053/j.gastro.2014.02.009 PubMed DOI PMC

Schwiertz A, Jacobi M, Frick JS, Richter M, Rusch K, Kohler H. Microbiota in pediatric inflammatory bowel disease. J Pediatr. 2010;157(2):240–4 e1 Epub 2010/04/20. 10.1016/j.jpeds.2010.02.046 . PubMed DOI

Gevers D, Kugathasan S, Denson LA, Vazquez-Baeza Y, Van Treuren W, Ren B, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014;15(3):382–92. Epub 2014/03/19. 10.1016/j.chom.2014.02.005 PubMed DOI PMC

Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol. 2007;115(1):1–11. Epub 2006/12/02. 10.1016/j.ijfoodmicro.2006.10.006 . PubMed DOI

Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–14. 10.1038/nrgastro.2014.66 . PubMed DOI

Hart AL, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 2004;53(11):1602–9. Epub 2004/10/14. 10.1136/gut.2003.037325 PubMed DOI PMC

Latvala S. Potentially probiotic bacteria induce efficient maturation but differential cytokine production in human monocyte-derived dendritic cells. World Journal of Gastroenterology. 2008;14(36):5570 10.3748/wjg.14.5570 PubMed DOI PMC

Lopez P, Gueimonde M, Margolles A, Suarez A. Distinct Bifidobacterium strains drive different immune responses in vitro. Int J Food Microbiol. 2010;138(1–2):157–65. Epub 2010/01/15. 10.1016/j.ijfoodmicro.2009.12.023 . PubMed DOI

Medina M, Izquierdo E, Ennahar S, Sanz Y. Differential immunomodulatory properties of Bifidobacterium logum strains: relevance to probiotic selection and clinical applications. Clinical and experimental immunology. 2007;150(3):531–8. Epub 2007/10/25. 10.1111/j.1365-2249.2007.03522.x PubMed DOI PMC

Preising J, Philippe D, Gleinser M, Wei H, Blum S, Eikmanns BJ, et al. Selection of bifidobacteria based on adhesion and anti-inflammatory capacity in vitro for amelioration of murine colitis. Appl Environ Microbiol. 2010;76(9):3048–51. 10.1128/AEM.03127-09 PubMed DOI PMC

Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75(2):263–74. . PubMed

Steidler L. Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10. Science. 2000;289(5483):1352–5. 10.1126/science.289.5483.1352 PubMed DOI

Dong H, Rowland I, Yaqoob P. Comparative effects of six probiotic strains on immune function in vitro. Br J Nutr. 2012;108(3):459–70. Epub 2011/11/08. 10.1017/S0007114511005824 . PubMed DOI

Kekkonen R-A. Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults. World Journal of Gastroenterology. 2008;14(13):2029 10.3748/wjg.14.2029 PubMed DOI PMC

Mann ER, Landy JD, Bernardo D, Peake ST, Hart AL, Al-Hassi HO, et al. Intestinal dendritic cells: their role in intestinal inflammation, manipulation by the gut microbiota and differences between mice and men. Immunol Lett. 2013;150(1–2):30–40. Epub 2013/01/29. 10.1016/j.imlet.2013.01.007 . PubMed DOI

Steinbach EC, Plevy SE. The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm Bowel Dis. 2014;20(1):166–75. Epub 2013/08/27. 10.1097/MIB.0b013e3182a69dca PubMed DOI PMC

Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, Poiret S, et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol. 2007;13(2):236–43. PubMed PMC

Kwon HK, Lee CG, So JS, Chae CS, Hwang JS, Sahoo A, et al. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A. 2010;107(5):2159–64. 10.1073/pnas.0904055107 PubMed DOI PMC

Mileti E, Matteoli G, Iliev ID, Rescigno M. Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PloS one. 2009;4(9):e7056 Epub 2009/09/17. 10.1371/journal.pone.0007056 PubMed DOI PMC

Karczewski J, Troost FJ, Konings I, Dekker J, Kleerebezem M, Brummer RJ, et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. American journal of physiology Gastrointestinal and liver physiology. 2010;298(6):G851–9. 10.1152/ajpgi.00327.2009 . PubMed DOI

Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411(6837):603–6. 10.1038/35079114 . PubMed DOI

Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411(6837):599–603. 10.1038/35079107 . PubMed DOI

Biswas A, Kobayashi KS. Regulation of intestinal microbiota by the NLR protein family. International immunology. 2013;25(4):207–14. 10.1093/intimm/dxs116 PubMed DOI PMC

Couturier-Maillard A, Secher T, Rehman A, Normand S, De Arcangelis A, Haesler R, et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. The Journal of clinical investigation. 2013;123(2):700–11. 10.1172/JCI62236 PubMed DOI PMC

Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. The Journal of biological chemistry. 2003;278(8):5509–12. 10.1074/jbc.C200673200 . PubMed DOI

Macho Fernandez E, Valenti V, Rockel C, Hermann C, Pot B, Boneca IG, et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut. 2011;60(8):1050–9. 10.1136/gut.2010.232918 . PubMed DOI

Pastorelli L, De Salvo C, Mercado JR, Vecchi M, Pizarro TT. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol. 2013;4:280 Epub 2013/09/26. 10.3389/fimmu.2013.00280 PubMed DOI PMC

Schulzke JD, Ploeger S, Amasheh M, Fromm A, Zeissig S, Troeger H, et al. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci. 2009;1165:294–300. Epub 2009/06/23. 10.1111/j.1749-6632.2009.04062.x . PubMed DOI

Buning C, Geissler N, Prager M, Sturm A, Baumgart DC, Buttner J, et al. Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease? Inflamm Bowel Dis. 2012;18(10):1932–9. Epub 2012/02/22. 10.1002/ibd.22909 . PubMed DOI

Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014;7(1):6–19. 10.1038/mi.2013.73 . PubMed DOI

Gyires K, Toth EV, Zadori SZ. Gut inflammation: current update on pathophysiology, molecular mechanism and pharmacological treatment modalities. Curr Pharm Des. 2014;20(7):1063–81. . PubMed

Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PloS one. 2007;2(12):e1308 10.1371/journal.pone.0001308 PubMed DOI PMC

Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol. 2007;9(3):804–16. Epub 2006/11/08. 10.1111/j.1462-5822.2006.00836.x . PubMed DOI

Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. American journal of physiology Gastrointestinal and liver physiology. 2009;296(5):G1140–9. 10.1152/ajpgi.90534.2008 . PubMed DOI

Priority order of neonatal colonization by a probiotic or pathogenic Escherichia coli strain dictates the host response to experimental colitis

Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice

Viability Status-Dependent Effect of Bifidobacterium longum ssp. longum CCM 7952 on Prevention of Allergic Inflammation in Mouse Model

Pre- and Neonatal Imprinting on Immunological Homeostasis and Epithelial Barrier Integrity by Escherichia coli Nissle 1917 Prevents Allergic Poly-Sensitization in Mice

Germ-Free Mice Exhibit Mast Cells With Impaired Functionality and Gut Homing and Do Not Develop Food Allergy

Immunoreactive Proteins of Bifidobacterium longum ssp. longum CCM 7952 and Bifidobacterium longum ssp. longum CCDM 372 Identified by Gnotobiotic Mono-Colonized Mice Sera, Immune Rabbit Sera and Non-immune Human Sera